Literature DB >> 12812304

Tuberculosis of the pituitary and sellar region.

Pamela U Freda.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12812304     DOI： 10.1023/a:1023363429570

Source DB:  PubMed          Journal:  Pituitary        ISSN： 1386-341X            Impact factor:   4.107


× No keyword cloud information.
  6 in total

Review 1.  Laboratory diagnosis of central nervous system infections.

Authors:  R B Thomson; H Bertram
Journal:  Infect Dis Clin North Am       Date:  2001-12       Impact factor: 5.982

2.  An unusual pituitary pathology.

Authors:  P Petrossians; P Delvenne; P Flandroy; P Jopart; A Stevenaert; A Beckers
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

3.  Unusual causes of sellar/parasellar masses in a large transsphenoidal surgical series.

Authors:  P U Freda; S L Wardlaw; K D Post
Journal:  J Clin Endocrinol Metab       Date:  1996-10       Impact factor: 5.958

Review 4.  Differential diagnosis of sellar masses.

Authors:  P U Freda; K D Post
Journal:  Endocrinol Metab Clin North Am       Date:  1999-03       Impact factor: 4.741

Review 5.  Intrasellar tuberculoma--an enigmatic pituitary infection: a series of 18 cases.

Authors:  M C Sharma; R Arora; A K Mahapatra; P Sarat-Chandra; S B Gaikwad; C Sarkar
Journal:  Clin Neurol Neurosurg       Date:  2000-06       Impact factor: 1.876

6.  Sellar tuberculoma: report of two cases.

Authors:  K Ashkan; M C Papadopoulos; A T Casey; D N Thompson; S Jarvis; M Powell; D G Thomas
Journal:  Acta Neurochir (Wien)       Date:  1997       Impact factor: 2.216
  6 in total
  2 in total

1.  Primary CNS lymphoma with bilateral symmetric hypothalamic lesions presenting with panhypopituitarism and diabetes insipidus.

Authors:  Brian Thomas Layden; Steve Dubner; Daniel J Toft; Peter Kopp; Sean Grimm; Mark E Molitch
Journal:  Pituitary       Date:  2011-06       Impact factor: 4.107

2.  Treatment of neuro-ophthalmologic manifestations of tuberculosis.

Authors:  Susannah Mistr; Pamela S Chavis
Journal:  Curr Treat Options Neurol       Date:  2006-01       Impact factor: 3.972
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.